Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GX-19N COVID-19 Vaccine in Elderly Individuals
NCT04915989Phase 1Completed
- Sponsor
- Genexine
- Start
- Feb 2021
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GX-19N in coronavirus disease 2019 (COVID-19), sponsored by Genexine. Primary endpoints: Incidence of Solicited Adverse Events at 1 year, Incidence of Unsolicited Adverse Events at 1 year and 1 more. Started Feb 2021; status: completed.
02
Drugs
GX-19N
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04915989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915989.